We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Innovate Biopharmaceuticals Inc | NASDAQ:INNT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.56 | 0.56 | 0.57 | 0 | 01:00:00 |
Delaware
|
|
27-3948465
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
8480 Honeycutt Road, Suite 120
Raleigh, North Carolina
|
|
27615
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Large accelerated filer
|
o
|
|
Accelerated filer
|
o
|
Non-accelerated filer
|
þ
|
|
Smaller reporting company
|
þ
|
|
|
|
Emerging growth company
|
þ
|
Title of Securities To Be Registered
|
Amount To Be Registered
|
Proposed Maximum Offering Price Per Share
|
Proposed Maximum Aggregate Offering Price
|
Amount of Registration Fee
|
Common Stock, $0.0001 per value per share
|
3,000,000 (1)
|
$2.68 (2)
|
$8,040,000 (2)
|
$974.45 (2)
|
(1)
|
This Registration Statement covers 3,000,000 shares of Common Stock, $0.0001 par value per share, that are authorized for issuance under the Registrant’s 2012 Omnibus Incentive Plan, as amended. In addition, pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution of the shares of Common Stock covered hereby resulting from stock splits, stock dividends or similar transactions.
|
(2)
|
Calculated solely for the purpose of this offering pursuant to Rule 457(h) on the basis of the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on December 13, 2018.
|
Exhibit No.
|
Description
|
5.1
|
|
23.1
|
|
23.2
|
|
23.3
|
Consent of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. (Contained in Exhibit 5.1)
|
24.1
|
Power of Attorney (Contained on signature page)
|
99.1
|
|
|
|
|
Innovate Biopharmaceuticals, Inc.
|
|
|
|
|
|
By:
|
/s/ Christopher Prior, Ph.D.
|
|
|
Christopher Prior, Ph.D.
|
|
|
Chief Executive Officer and Director
|
Name
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Christopher Prior, Ph.D.
|
|
Chief Executive Officer and Director
|
|
December 14, 2018
|
Christopher Prior, Ph.D.
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Jay P. Madan
|
|
President, Chief Business Officer, Interim Principal Financial Officer, Interim Principal Accounting Officer and Director
|
|
December 14, 2018
|
Jay P. Madan, M.S.
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Sandeep Laumas, M.D.
|
|
Director
|
|
December 14, 2018
|
Sandeep Laumas, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Lorin K. Johnson, Ph.D.
|
|
Director
|
|
December 14, 2018
|
Lorin K. Johnson, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Anthony E. Maida III, Ph.D.
|
|
Director
|
|
December 14, 2018
|
Anthony E. Maida III, Ph.D., M.A., M.B.A.
|
|
|
|
|
|
|
|
|
|
/s/ Roy Proujansky, M.D.
|
|
Director
|
|
December 14, 2018
|
Roy Proujansky, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Saira Ramasastry
|
|
Director
|
|
December 14, 2018
|
Saira Ramasastry, M.S., M.Phil.
|
|
|
|
|
|
|
|
|
|
1 Year Innovate Biopharmaceutic... Chart |
1 Month Innovate Biopharmaceutic... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions